Prevalence of Left Ventricular Systolic Dysfunction in Myotonic Dystrophy Type 1: A Systematic Review
- PMID: 31415861
- DOI: 10.1016/j.cardfail.2019.07.548
Prevalence of Left Ventricular Systolic Dysfunction in Myotonic Dystrophy Type 1: A Systematic Review
Abstract
Cardiac involvement is recorded in about 80% of patients affected by myotonic dystrophy type 1 (DM1). The prevalence of cardiac conduction abnormalities and arrhythmias has been well described. Data regarding the prevalence of left ventricle systolic dysfunction (LVSD) and heart failure (HF) are still conflicting. The primary objective of this review was to assess the prevalence of LVSD and HF in DM1. The secondary aim was to examine the association of clinical features with LVSD and to detect predisposing and influencing prognosis factors. A systematic search was developed in MEDLINE, EMBASE, Cochrane Register of Controlled Trials, and Web of Science databases to identify original reports between January 1, 2009, and September 30, 2017, assessing the prevalence of LVSD and HF in populations with DM1. Retrospective and prospective cohort studies and case series describing the prevalence of LVSD, as evaluated by echocardiography, and HF in patients with DM1 were included. Case reports, simple reviews, commentaries and editorials were excluded. Seven studies were identified as eligible, of which 1 was a retrospective population-based cohort study, and 6 were retrospective single-center-based cohort studies. Echocardiographic data concerning LV function were available for 647 of the 876 patients with DM1 who were included in the analysis. The prevalence of LVSD in patients with DM1, defined as LVEF < 55%, was 13.8%, 4.5-fold higher than in general population. Patients with DM1 and LVSD were older, were more likely to be male, had longer baseline atrioventricular and intraventricular conduction-time durations, had higher incidences of atrial arrhythmias, and were more likely to have undergone device implantation. Also, symptomatic HF is more prevalent in patients with DM1 despite their limited levels of physical activity. Further studies are needed to evaluate the prevalence of LVSD and HF in patients with DM1 and to investigate electrocardiographic abnormalities and other clinical features associated with this condition.
Keywords: Myotonic dystrophy type 1; heart failure; left ventricle systolic dysfunction.
Copyright © 2019 Elsevier Inc. All rights reserved.
Similar articles
-
Increased mortality with left ventricular systolic dysfunction and heart failure in adults with myotonic dystrophy type 1.Am Heart J. 2010 Dec;160(6):1137-41, 1141.e1. doi: 10.1016/j.ahj.2010.07.032. Am Heart J. 2010. PMID: 21146669 Clinical Trial.
-
Prevalence of atrial fibrillation in myotonic dystrophy type 1: A systematic review.Neuromuscul Disord. 2021 Apr;31(4):281-290. doi: 10.1016/j.nmd.2021.01.002. Epub 2021 Jan 9. Neuromuscul Disord. 2021. PMID: 33573883
-
Routine echocardiography in patients with myotonic dystrophy type 1.J Chin Med Assoc. 2017 Jul;80(7):408-412. doi: 10.1016/j.jcma.2017.04.004. Epub 2017 Jun 7. J Chin Med Assoc. 2017. PMID: 28601625
-
Combined Circumferential and Longitudinal Left Ventricular Systolic Dysfunction in Patients with Rheumatoid Arthritis without Overt Cardiac Disease.J Am Soc Echocardiogr. 2016 Jul;29(7):689-98. doi: 10.1016/j.echo.2016.01.004. Epub 2016 Feb 24. J Am Soc Echocardiogr. 2016. PMID: 26922258
-
Prevalence of left ventricular systolic dysfunction and heart failure with reduced ejection fraction in men and women with type 2 diabetes mellitus: a systematic review and meta-analysis.Cardiovasc Diabetol. 2018 Apr 18;17(1):58. doi: 10.1186/s12933-018-0690-3. Cardiovasc Diabetol. 2018. PMID: 29669564 Free PMC article.
Cited by
-
Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.Hum Mol Genet. 2020 Jun 3;29(9):1440-1453. doi: 10.1093/hmg/ddaa060. Hum Mol Genet. 2020. PMID: 32242217 Free PMC article.
-
Predictors of prognosis in type 1 myotonic dystrophy (DM1): longitudinal 18-years experience from a single center.Acta Myol. 2020 Sep 1;39(3):109-120. doi: 10.36185/2532-1900-015. eCollection 2020 Sep. Acta Myol. 2020. PMID: 33305167 Free PMC article.
-
Non-invasive ventilation in neuromuscular diseases: should we use higher levels of ventilatory support?Sleep Breath. 2023 May;27(2):673-677. doi: 10.1007/s11325-022-02658-3. Epub 2022 Jun 20. Sleep Breath. 2023. PMID: 35725863 Clinical Trial.
-
Comprehensive Cardiovascular Management of Myotonic Dystrophy Type 1 Patients: A Report from the Italian Neuro-Cardiology Network.J Cardiovasc Dev Dis. 2024 Feb 16;11(2):63. doi: 10.3390/jcdd11020063. J Cardiovasc Dev Dis. 2024. PMID: 38392277 Free PMC article. Review.
-
Echocardiographic Features of Cardiac Involvement in Myotonic Dystrophy 1: Prevalence and Prognostic Value.J Clin Med. 2023 Mar 1;12(5):1947. doi: 10.3390/jcm12051947. J Clin Med. 2023. PMID: 36902735 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous